$NVO (~$46.68) \vert{}$LLY (~$1118.01) The battle between pharma titans is reigniting as Novo Nordisk moves aggressively to reclaim US market share lost to Eli Lilly. The next-gen Wegovy pill gives Novo an edge as competition escalates in a projected $100B weight-loss TAM. The shift from injections to oral pills is the endgame. Orals dramatically lower user friction whichever giant scales supply first will unlock the next wave of retail adoption! Bet on $NVO 's oral comeback or $LLY 's market lead?
136 views
0 Comments
Join the conversation with 500,000+ other investors 💸
Create an account to get access to everything Blossom has to offer!
📊 Personalized algorithm based on your investing style, experience level and interests
📈 Powerful portfolio and dividend tracking tools
👀 See what top creators and others in the community are investing in
